Asset profile
CAB-ROR2-ADC
Unknown / undisclosed
Evidence outlook · lead readout
NCT03504488 · Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT03504488: The study randomized 132 participants between two treatment regimens, but it was open-label and had no placebo or established active-control arm. Its Phase 2 primary efficacy measure was confirmed objective tumor response, a clinical endpoint, but no primary-endpoint result has been posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.